Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akeso Inc.
Deal Snapshot: Akeso has already sought to secure FDA approval for its PD-1 inhibitor, but the agency has shown reluctance to approve drugs based on China-only data.
The annual reimbursement price negotiations between pharma firms and China’s National Healthcare Security Administration are just around the corner. While some have chosen to walk away from the process completely, others including majors BeiGene and Hengrui are girding up for another round of potentially deep cuts.
In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.
Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines.
- Large Molecule
- Other Names / Subsidiaries
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology